Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lane Labs BeneFin Is Unapproved Drug - FDA Complaint

This article was originally published in The Tan Sheet

Executive Summary

FDA is seeking a permanent injunction against the sale of Lane Labs-USA's BeneFin, SkinAnswer and MGN-3 products, alleging they are "unapproved drugs" and "illegally promoted as treatments for cancer and other diseases."
Advertisement

Related Content

Lane Labs To Pay Consumer Restitution Under Permanent Injunction
Lane Labs To Pay Consumer Restitution Under Permanent Injunction
Lane Labs To Pay Consumer Restitution Under Permanent Injunction
DSHEA Third-Party Literature Constraints Violate First Amendment – Lawsuit
Lane Labs FTC Settlement To Fund National Cancer Institute Study
Lane Labs USA
FDA Criminal Investigations Of Unapproved Drug Internet Sales Ongoing
NCI Phase III Trial On Shark Cartilage May Begin Recruitment Summer/Fall
FDA awaiting shark cartilage cancer claims opinion on Lane Labs, William Lane.
FDA awaiting shark cartilage cancer claims opinion on Lane Labs, William Lane.

Topics

Advertisement
UsernamePublicRestriction

Register

PS090697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel